VIP is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
VIP is one of the most discussed peptides in the research community, with reports focusing on its effects on vasodilation, bronchodilation, anti-inflammatory effects, neuroprotection, lung function improvement. Phase 3 TESICO trial (471 patients with COVID-19) halted for futility with IV dosing. Phase 2 RCT (80 subjects, inhaled) showed positive signal. Orphan drug designation for pulmonary hypertension. Limited human data; research ongoing.
What Do Researchers Report About VIP?
VIP (Vasoactive Intestinal Peptide) is one of the most discussed Neuropeptide, vasodilator, anti-inflammatory compounds in the peptide research community. Reports span effects on vasodilation, bronchodilation, anti-inflammatory effects, neuroprotection, lung function improvement.
Phase 3 TESICO trial (471 patients with COVID-19) halted for futility with IV dosing. Phase 2 RCT (80 subjects, inhaled) showed positive signal. Orphan drug designation for pulmonary hypertension. Limited human data; research ongoing.
What Are the Most Common Positive Reports?
Researchers frequently cite VIP's effects on vasodilation, bronchodilation, anti-inflammatory effects, neuroprotection, lung function improvement as the primary benefits observed during standard cycles of ongoing continuous therapy.
The only peptide addressing vasodilation, bronchoprotection, AND neuroprotection through a single receptor family — but its 2-minute half-life makes practical delivery the primary challenge. This distinctive profile is a key reason VIP maintains its popularity despite the growing number of alternatives.
What Are the Common Criticisms?
The most common complaints about VIP: Limited clinical data. Nasal irritation possible. Short half-life limits systemic toxicity. Well-tolerated in preliminary studies.
Cost and sourcing quality are also frequent concerns — results vary significantly between vendors, which is why COA testing is essential.
How Does VIP Compare to Alternatives?
As a Neuropeptide, vasodilator, anti-inflammatory, VIP competes with several similar compounds. The only peptide addressing vasodilation, bronchoprotection, AND neuroprotection through a single receptor family — but its 2-minute half-life makes practical delivery the primary challenge.
Combines with inhaled corticosteroids or bronchodilators for synergistic airway relaxation in asthma/COPD.
Bottom Line: Is VIP Worth It?
Based on the available research and community reports, VIP is well-regarded for vasodilation, bronchodilation, anti-inflammatory effects, neuroprotection, lung function improvement. The key factors for success: consistent dosing (50-100 mcg per spray or 200 mcg daily inhaled 4 times daily (nasal) or daily (inhaled)), quality sourcing, and realistic expectations over ongoing continuous therapy cycles.
Complete Guide
VIP : Benefits, Dosage, Side Effects & Research
Related Reading
Calculate Your VIP Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for VIP.
Open Calculator →Research-Grade Sourcing
If you're going to research VIP, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is VIP?
VIP (Vasoactive Intestinal Peptide) is a Neuropeptide, vasodilator, anti-inflammatory. Endogenous 28-amino acid neuropeptide produced in gut, pancreas, brain, and neuroendocrine tissues. It is researched for vasodilation, bronchodilation, anti-inflammatory effects, neuroprotection, lung function improvement.
What is the recommended VIP dosage?
Common dosages: 50-100 mcg per spray or 200 mcg daily inhaled administered 4 times daily (nasal) or daily (inhaled) via intranasal spray or inhalation. Cycle length: ongoing continuous therapy. Half-life: 2 minutes (extremely short). Use our peptide calculator for exact reconstitution math.
What are the side effects of VIP?
Limited clinical data. Nasal irritation possible. Short half-life limits systemic toxicity. Well-tolerated in preliminary studies.
Is VIP safe?
VIP has shown a favorable safety profile in research. Not FDA-approved. Orphan drug designation for pulmonary hypertension. FDA announced plans to remove from compounding lists. All research should follow appropriate safety protocols.